The number of Canadians using medical cannabis has increased significantly in recent years. Since 2017, there has been a 70% increase in the number of registrants authorized to use medical cannabis. As of September 2018, there were 342,103 authorizations to use medical cannabis.
Patients and physicians are faced with the daunting task of deciding how to select the right strain, what works, how much to take, and when.
Though there is quality evidence for some medical conditions and symptoms – such as chronic pain, Multiple Sclerosis, treatment-resistant epilepsy, and nausea and vomiting related to chemotherapy – there is a significant lack of evidence for many conditions.
Legalization of cannabis has been contentious within the federal landscape and has arguably created confusion among the medical community.
As a result, we believe that patients can lead the change in the healthcare system for the ﬁrst time. Further, we believe that empowered patients should have a large-scale patient-centric solution that allows them to collect their own data and is accepted by the medical community.
Here’s where the Reformulary Group comes in: Cannabis Standard is a new formulary model that leverages digital channels to survey patients at scale, using metrics and surveys that are validated and reviewed by medical experts.
Powered by the Partner platform, the platform will be fuelled by patients reporting their own outcomes data, in-real-time and as-needed data.
By empowering patients to record and share their data proactively, they will be able to make smarter medical cannabis decisions for their condition, while contributing to evidence that will help shape the future of medical cannabis use.